J. McNally

658 total citations
33 papers, 474 citations indexed

About

J. McNally is a scholar working on Hepatology, Rheumatology and Epidemiology. According to data from OpenAlex, J. McNally has authored 33 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 9 papers in Rheumatology and 8 papers in Epidemiology. Recurrent topics in J. McNally's work include Hepatitis C virus research (24 papers), Systemic Lupus Erythematosus Research (9 papers) and HIV/AIDS drug development and treatment (7 papers). J. McNally is often cited by papers focused on Hepatitis C virus research (24 papers), Systemic Lupus Erythematosus Research (9 papers) and HIV/AIDS drug development and treatment (7 papers). J. McNally collaborates with scholars based in United States, Canada and Italy. J. McNally's co-authors include G W Mertz, Brien A. Holden, Diana M. Brainard, Hadas Dvory‐Sobol, John P. Dalton, John G. McHutchison, Krishna Chodavarapu, David Wyles, Hongmei Mo and Alessandra Mangia and has published in prestigious journals such as Journal of Experimental Botany, Journal of Hepatology and Parasitology.

In The Last Decade

J. McNally

31 papers receiving 444 citations

Peers

J. McNally
DeGaulle I. Chigbu United States
Ornella Zuccaro Italy
P. Moncharmont France
Kathryn M. Zunich United States
Saul Ullman United States
Julien Marlet France
J. Benjamin St. Clair United States
C. C. Davey United Kingdom
Jacqueline Cottalorda France
DeGaulle I. Chigbu United States
J. McNally
Citations per year, relative to J. McNally J. McNally (= 1×) peers DeGaulle I. Chigbu

Countries citing papers authored by J. McNally

Since Specialization
Citations

This map shows the geographic impact of J. McNally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. McNally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. McNally more than expected).

Fields of papers citing papers by J. McNally

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. McNally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. McNally. The network helps show where J. McNally may publish in the future.

Co-authorship network of co-authors of J. McNally

This figure shows the co-authorship network connecting the top 25 collaborators of J. McNally. A scholar is included among the top collaborators of J. McNally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. McNally. J. McNally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McNally, J., et al.. (2024). Turgor pressure affects transverse stiffness and resonant frequencies of buzz-pollinated poricidal anthers. Journal of Experimental Botany. 76(6). 1784–1794. 1 indexed citations
2.
Bhardwaj, Neeru, Manon Ragonnet‐Cronin, Ben Murrell, et al.. (2017). Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens. Journal of Viral Hepatitis. 25(4). 344–353.
3.
Lai, Ching‐Lung, et al.. (2017). Sofosbuvir/velpatasvir for 12 weeks results in high SVR12 rates with a favorable safety profile in asian patients: an integrated subgroup analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies. 1 indexed citations
4.
Bourlière, Marc, Edward Gane, Stuart C. Gordon, et al.. (2017). Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA-based therapy: Results from the gilead SVR registry.. 66. 5 indexed citations
5.
Gane, Edward, K. Peter Etzkorn, G. Morelli, et al.. (2016). Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study. Journal of Hepatology. 64(2). S147–S148. 23 indexed citations
6.
Asselah, Tarik, Stephen Shafran, Sharon Bourgeois, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study). Journal of Hepatology. 64(2). S827–S828. 1 indexed citations
7.
8.
Hézode, Christophe, Nancy Reau, Evguenia S. Svarovskaia, et al.. (2016). Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies. Journal of Hepatology. 64(2). S399–S400. 14 indexed citations
9.
Wyles, David, Norbert Bräu, Eric S. Daar, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study. Journal of Hepatology. 64(2). S188–S189. 24 indexed citations
10.
11.
Lawitz, Eric, Bradley Freilich, John O. Link, et al.. (2015). A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Journal of Viral Hepatitis. 22(12). 1011–1019. 38 indexed citations
12.
Dvory‐Sobol, Hadas, David Wyles, Wen Ouyang, et al.. (2015). O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Journal of Hepatology. 62. S221–S221. 55 indexed citations
13.
Cheng, Wei, Stephen D. Shafran, Kimberly L. Beavers, et al.. (2014). P1112 LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES. Journal of Hepatology. 60(1). S449–S449. 9 indexed citations
14.
Aggarwal, A., J. McNally, Luisa M. Stamm, et al.. (2014). P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES. Journal of Hepatology. 60(1). S475–S475. 4 indexed citations
15.
Läwitz, E., Mitchell Davis, M. Rodríguez‐Torres, et al.. (2013). 1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY. Journal of Hepatology. 58. S567–S567. 6 indexed citations
16.
Jacobson, Ira M., Eric M. Yoshida, Mark Sulkowski, et al.. (2013). 61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL. Journal of Hepatology. 58. S28–S28. 8 indexed citations
17.
Marcellin, Patrick, E.J. Heathcote, Thomas Berg, et al.. (2011). 739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES. Journal of Hepatology. 54. S296–S297. 6 indexed citations
18.
Никитин, И. Г., A. A. Yakovlev, Pavel Bogomolov, et al.. (2007). [11] PHASE 2 STUDY OF OMEGA INTERFERON ALONE OR IN COMBINATION WITH RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION. Journal of Hepatology. 46. S8–S8. 16 indexed citations
19.
Dalton, John P., et al.. (1993). In vitro assays for the study of erythrocyte invasion by malarial parasites. Parasitology Today. 9(3). 109–111. 4 indexed citations
20.
McNally, J., et al.. (1992). Plasmodium bergheiandPlasmodium chabaudi chabaudi: development of simplein vitroerythrocyte invasion assays. Parasitology. 105(3). 355–362. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by DeGaulle I. Chigbu Breakdown of academic impact, for papers by Ornella Zuccaro Breakdown of academic impact, for papers by P. Moncharmont Breakdown of academic impact, for papers by Kathryn M. Zunich Breakdown of academic impact, for papers by Saul Ullman Breakdown of academic impact, for papers by Julien Marlet Breakdown of academic impact, for papers by J. Benjamin St. Clair Breakdown of academic impact, for papers by C. C. Davey Breakdown of academic impact, for papers by Jacqueline Cottalorda
Rankless by CCL
2026